Switch View
© PR Newswire
15.09.2025
ISIN: CA23126M1023
Curaleaf Holdings Inc
CURA
LISTED
TSX
Curaleaf Expands Retail Footprint with Dispensary Openings in Florida and Ohio
News Preview
New locations in Apopka, Florida and Girard, Ohio bring Curaleaf's nationwide store count to 157
STAMFORD, Conn., Sept. 15, 2025 /CNW/ -- Curaleaf Holdings, Inc. (TSX: CURA) (OTCQX: CURLF) ("Curaleaf" or the "Company"), a leading international provider of consumer cannabis products, today announced the opening of two new dispensaries; Curaleaf Ap...
Themefolio
Profiler
Peergroup
© BusinessWire
15.09.2025
ISIN: US92790C1045
Viridian Therapeutics Inc
VRDN
LISTED
NASDAQ
Viridian Therapeutics Announces Completion of Enrollment in both REVEAL Clinical Trials and Positive Portfolio Updates
News Preview
Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering, developing and commercializing potential best-in-class medicines for serious and rare diseases, today announced that enrollment is complete in REVEAL-1 and REVEAL-2, phase 3 clinical trials for VRDN-003 in patients with active and chronic TED, respectively....
Themefolio
Profiler
Peergroup
© PR Newswire
15.09.2025
ISIN: US50015M1099
Kodiak Sciences Inc
KOD
LISTED
NASDAQ
New data for Kodiak's KSI-101 from the APEX study reinforce its clinically meaningful vision gains and rapid retinal drying in macular edema secondary to inflammation (MESI)
News Preview
Meaningful vision gains are rapidly achieved as early as week 4 and more than half of patients in the top two dose levels improved 3-lines or more on the eye chart (≥15 letter gain)A single dose of KSI-101 resulted in the majority of patients achieving resolution of intra-retinal and sub-retinal fluid and over 90% of patients achieved retinal dry...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Leerverkaufsstatistiken, Hedge-Fund Aktivitäten und viele weitere nutzerwertige Informationen benutzerfreundlich aufbereitet
© PR Newswire
15.09.2025
ISIN: US05350V1061
Avanos Medical Inc
AVNS
LISTED
NYSE
Avanos Medical Acquires Nexus Medical to Strengthen Nutrition and Medication Delivery in Critical Care
News Preview
ALPHARETTA, Ga., Sept. 15, 2025 /PRNewswire/ -- Avanos Medical, Inc. (NYSE: AVNS), a leading medical technology company, today announced the acquisition of Nexus Medical, LLC, a privately held medical device company based in Lenexa, Kansas....
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© PR Newswire
15.09.2025
ISIN: CA39986R1064
Grown Rogue International Inc.
GRIN
LISTED
CSE
Grown Rogue Expands Senior Credit Facility by US$5 Million
News Preview
Brings Total Facility to US$12 Million; Proceeds to Support Growth Initiatives
MEDFORD, Ore., Sept. 15, 2025 /CNW/ - Grown Rogue International Inc. ("Grown Rogue" or the "Company") (CSE: GRIN) (OTC: GRUSF), a flower-forward cannabis company combining craft values with disciplined execution, today announced it has secured an incremental US$5 milli...
Themefolio
Profiler
Peergroup
© BusinessWire
15.09.2025
ISIN: CA1380357048
Canopy Growth Corp
CGC
LISTED
NASDAQ
Canopy Growth Strengthens Balance Sheet with Early US$25 Million Term Loan Prepayment
News Preview
Canopy Growth Corporation (“Canopy Growth” or the “Company”) (TSX: WEED) (Nasdaq: CGC), a world-leading cannabis company dedicated to unleashing the power of cannabis to improve lives, announced today that it completed an early prepayment of US$25 million (the “Prepayment”) against the Company’s senior secured term loan (the “Term Loan”).
The Co...
Themefolio
Profiler
Peergroup
© BusinessWire
15.09.2025
ISIN: US58933Y1055
Merck & Co Inc
MRK
LISTED
NYSE
Raludotatug Deruxtecan Granted Breakthrough Therapy Designation by U.S. FDA for Patients with CDH6 Expressing Platinum-Resistant Ovarian, Primary Peritoneal or Fallopian Tube Cancers Previously Treated with Bevacizumab
News Preview
Raludotatug deruxtecan (R-DXd) has been granted Breakthrough Therapy Designation (BTD) by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with platinum-resistant epithelial ovarian, primary peritoneal or fallopian tube cancers expressing CDH6 who have received prior treatment with bevacizumab.
Raludotatug deruxtec...
Themefolio
Profiler
Peergroup
© BusinessWire
15.09.2025
ISIN: JE00BYSS4X48
Novocure Ltd
NVCR
LISTED
NASDAQ
Novocure’s Optune Lua® Receives Approval in Japan for the Treatment of Unresectable Advanced/Recurrent Non-Small Cell Lung Cancer (NSCLC)
News Preview
Novocure (NASDAQ: NVCR) announced today that Japan’s Ministry of Health, Labour and Welfare (MHLW) approved Optune Lua® for concurrent use with PD-1/PD-L1 inhibitors for the treatment of adult patients with unresectable advanced/recurrent non-small cell lung cancer (NSCLC) who have progressed on or after platinum-based chemotherapy.
“With the Mi...
Themefolio
Profiler
Peergroup
© Globe Newswire
15.09.2025
ISIN: US29089Q1058
Emergent BioSolutions Inc
EBS
LISTED
NYSE
Emergent BioSolutions Secures $17 Million Contract Modification for Oral Suspension TEMBEXA® (brincidofovir), a Smallpox Antiviral, and Strengthens Overall U.S. Supply Chain
News Preview
GAITHERSBURG, Md., Sept. 15, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced it has received a $17 million contract modification from the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and...
Themefolio
Profiler
Peergroup
© Globe Newswire
15.09.2025
ISIN: CA82621K1021
Sienna Senior Living Inc
SIA
LISTED
TSX
Sienna Announces September Dividend
News Preview
MARKHAM, Ontario, Sept. 15, 2025 (GLOBE NEWSWIRE) -- Sienna Senior Living Inc. (“Sienna” or the “Company”) (TSX: SIA) today announced a dividend of $0.078 per common share of the Company (each, a “Common Share”) for the month of September 2025, representing $0.936 per Common Share on an annualized basis....
Themefolio
Profiler
Peergroup
© Globe Newswire
15.09.2025
ISIN: AU000000ACW3
Actinogen Medical Limited
ACW
LISTED
ASX
Actinogen achieves agreement with the FDA in a Type C meeting on the manufacturing, clinical and nonclinical activities required for a future US marketing approval of Xanamem for Alzheimer’s disease
News Preview
Current XanaMIA pivotal phase 2/3 trial on track for interim analysis in January 2026 and final results late 2026 with trial enrolment expected to close in Q4 2025 Current XanaMIA pivotal phase 2/3 trial on track for interim analysis in January 2026 and final results late 2026 with trial enrolment expected to close in Q4 2025...
Themefolio
Profiler
Peergroup
© Globe Newswire
15.09.2025
ISIN: US1276361086
Cadrenal Therapeutics, Inc.
CVKD
LISTED
NASDAQ
Cadrenal Therapeutics Enhances Anticoagulation Pipeline Through Acquisition of eXIthera’s Portfolio of Factor XIa Inhibitors
News Preview
PONTE VEDRA, Fla., Sept. 15, 2025 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing transformative therapeutics to overcome the gaps in anticoagulation therapy, today announced the acquisition of the assets of eXIthera Pharmaceuticals (“eXIthera”), including its proprietary portfolio of investi...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© Globe Newswire
15.09.2025
ISIN: CA3018351047
Extendicare Inc
EXE
LISTED
TSX
Extendicare Announces September 2025 Dividend of C$0.042 per Share
News Preview
MARKHAM, Ontario, Sept. 15, 2025 (GLOBE NEWSWIRE) -- Extendicare Inc. (“Extendicare” or the “Company”) (TSX: EXE) announced that it has declared a cash dividend of C$0.042 per common share of the Company for the month of September 2025, which is payable on October 15, 2025 to shareholders of record at the close of business on September 30, 2025....
Themefolio
Profiler
Peergroup
© Globe Newswire
15.09.2025
ISIN: US45782T1051
INmune Bio, Inc.
INMB
LISTED
NASDAQ
INmune Bio Announces Successful Completion of First Commercial Pilot-Scale Manufacturing Run of CORDStrom™ at CGT Catapult
News Preview
BOCA RATON, Fla., Sept. 15, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (“INmune” or “the Company”), a clinical-stage inflammation and immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today announced the successful completion of its first full-scale pilot commercial...
Themefolio
Profiler
Peergroup
© Globe Newswire
15.09.2025
ISIN: US59503A2042
Microbot Medical Inc.
MBOT
LISTED
NASDAQ
Microbot Medical Announces Exercise of Outstanding Preferred Investment Options for Up to $92.2 Million in Gross Proceeds
News Preview
$25.2 million in first closing and $4 million in second closing, with up to an additional approximately $63 million of potential aggregate gross proceeds upon the exercise in full of short-term preferred investment options $25.2 million in first closing and $4 million in second closing, with up to an additional approximately $63 million of potentia...
Themefolio
Profiler
Peergroup
© Globe Newswire
15.09.2025
ISIN: US5011471027
Krystal Biotech Inc
KRYS
LISTED
NASDAQ
Krystal Biotech Announces FDA Approval of Updated VYJUVEK® Label
News Preview
Revised label allows treatment of DEB patients from birth...
Themefolio
Profiler
Peergroup
© Globe Newswire
15.09.2025
ISIN: DK0062498333
Novo Nordisk A/S
NOVO B
LISTED
CPH
EU approval makes Novo Nordisk’s oral semaglutide the first and only oral GLP-1 RA to reduce cardiovascular death, heart attack and stroke
News Preview
Bagsværd, Denmark, 15 September 2025 – Novo Nordisk today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has approved an update to the Rybelsus® (oral semaglutide) label to reflect the cardiovascular benefits seen in the SOUL trial. SOUL was a phase 3b trial carried out to evaluate the eff...
Themefolio
Profiler
Peergroup
© Newsfile
15.09.2025
ISIN: CA41138T1057
Happy Belly Food Group Inc.
HBFG
LISTED
CSE
Happy Belly Food Group's Heal Wellness QSR Announces the Signing of a Franchise Agreement for Collingwood, Ontario
News Preview
Toronto, Ontario--(Newsfile Corp. - September 15, 2025) - Happy Belly Food Group Inc. (CSE: HBFG) (OTCQB: HBFGF) ("Happy Belly" or the "Company"), a leader in acquiring and scaling emerging food brands is pleased to announce that Heal Wellness has signed a franchise agreement for the Collingwood area of Ontario. Heal Wellness ("Heal") is a quick-se...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
15.09.2025
ISIN: US6986681004
PAO Group, Inc.
PAOG
LISTED
OTC
PAO Group Inc Announces New CEO James Schramm
News Preview
OMAHA, NE / ACCESS Newswire / September 15, 2025 / PAO Group, Inc. (OTC:PAOG), today announced the appointment of James Schramm as Chief Executive Officer of PAO Group, Inc. In a meeting of the Board of Directors, Mr. Schramm was named CEO and James C DiPrima will step down as CEO and remain Chief Financial Officer. The action was taken in response...
Themefolio
Profiler
Peergroup
© Globe Newswire
15.09.2025
ISIN: US6979471090
Palvella Therapeutics Inc
PVLA
LISTED
NASDAQ
Palvella Therapeutics Completes Enrollment in Phase 2 TOIVA Trial of QTORIN™ Rapamycin for Cutaneous Venous Malformations
News Preview
Phase 2 TOIVA trial successfully met recruitment target, enrolling 16 subjects at leading vascular anomaly centers; top-line data expected in mid-December 2025...
Themefolio
Profiler
Peergroup
© Globe Newswire
15.09.2025
ISIN: US02155H1014
Altimmune, Inc.
ALT
LISTED
NASDAQ
Altimmune Appoints Accomplished Commercial Executive Linda M. Richardson as Chief Commercial Officer
News Preview
GAITHERSBURG, Md., Sept. 15, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced the appointment of Linda M. Richardson to the role of Chief Commercial Officer, effective September 16, 2025. Ms. R...
Themefolio
Profiler
Peergroup
© Globe Newswire
15.09.2025
ISIN: US02155X2053
Alterity Therapeutics Limited
ATHE
LISTED
NASDAQ
Alterity Therapeutics Presents ATH434-201 Phase 2 Data at the American Neurological Association Annual Meeting
News Preview
ATH434 demonstrated clinically meaningful efficacy in modifying disease progression and was well tolerated at both 50 and 75 mg doses ATH434 demonstrated clinically meaningful efficacy in modifying disease progression and was well tolerated at both 50 and 75 mg doses...
Themefolio
Profiler
Peergroup
© Globe Newswire
15.09.2025
ISIN: US13471N3008
Can-Fite BioPharma Ltd.
CANF
LISTED
XASE
Can-Fite Reports Complete Resolution of Esophageal Varices in Decompensated Cirrhosis Patient Treated with Namodenoson
News Preview
Ramat Gan, Israel, Sept. 15, 2025 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company developing a pipeline of proprietary small molecule drugs targeting oncological and inflammatory diseases, today announced a significant new clinical finding under its compassionate use program in decompensated...
Themefolio
Profiler
Peergroup
© Globe Newswire
15.09.2025
ISIN: US4158581094
Harrow Inc
HROW
LISTED
NASDAQ
Harrow Announces Agenda and Speakers for Investor & Analyst Day
News Preview
NASHVILLE, Tenn., Sept. 15, 2025 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced the agenda for its upcoming Investor & Analyst Day on Friday, September 26, from 11:30 a.m. ET to 3 p.m. ET in New York. The event will also be webcast live and instru...
Themefolio
Profiler
Peergroup
© Globe Newswire
15.09.2025
ISIN: US61225M1027
Monte Rosa Therapeutics Inc
GLUE
LISTED
NASDAQ
Monte Rosa Therapeutics Announces Collaboration with Novartis for Degraders to Treat Immune-mediated Diseases
News Preview
Monte Rosa Therapeutics Announces Collaboration with Novartis for Degraders to Treat Immune-mediated Diseases...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
15.09.2025
ISIN: US74366E1029
Protagonist Therapeutics Inc
PTGX
LISTED
NASDAQ
Protagonist Announces Icotrokinra Phase 2b ANTHEM-UC Trial Data to be Presented at the United European Gastroenterology Week Berlin 2025
News Preview
NEWARK, CALIFORNIA / ACCESS Newswire / September 15, 2025 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") announced that data from the Phase 2b ANTHEM-UC study with icotrokinra in ulcerative colitis will be the focus of a brief oral presentation at the United European Gastroenterology Week 2025 being held in Be...
Themefolio
Profiler
Peergroup
© Globe Newswire
15.09.2025
ISIN: US67577C1053
Ocugen Inc
OCGN
LISTED
NASDAQ
Ocugen, Inc. and Kwangdong Pharmaceutical Co., Ltd. Complete License Agreement of OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in Korea
News Preview
MALVERN, Pa., Sept. 15, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today executed a licensing agreement with Kwangdong Pharmaceutical, Co., Ltd., (“Kwangdong”) one of the leading pharmaceutical companies in Korea, for the exclusive K...
Themefolio
Profiler
Peergroup
© PR Newswire
15.09.2025
ISIN: US02157Q1094
Alto Neuroscience, Inc.
ANRO
LISTED
NYSE
Alto Neuroscience, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - ANRO
News Preview
LOS ANGELES, Sept. 15, 2025 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Alto Neuroscience, Inc. ("Alto " or "the Company") (NYSE: ANRO ) for violations of the federal securities laws.
Shareholders who purchased shares of Alto during the class period listed are encouraged to contact the firm regarding po...
Themefolio
Profiler
Peergroup
© PR Newswire
15.09.2025
ISIN: US02157Q1094
Alto Neuroscience, Inc.
ANRO
LISTED
NYSE
ANRO Investors Have Opportunity to Lead Alto Neuroscience, Inc. Securities Fraud Lawsuit with the Schall Law Firm
News Preview
LOS ANGELES, Sept. 15, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces the firm has filed a class action lawsuit against Alto Neuroscience, Inc. ("Alto Neuroscience" or "the Company") (NYSE: ANRO) for violations of the federal securities laws....
Themefolio
Profiler
Peergroup
© BusinessWire
15.09.2025
ISIN: US2521311074
Dexcom Inc
DXCM
LISTED
NASDAQ
Dexcom Spotlights Upcoming Feature Launches, Improved Health Outcomes and Cost-Effectiveness With Dexcom Glucose Biosensing at EASD 2025
News Preview
DexCom, Inc. (Nasdaq: DXCM), a global leader in glucose biosensing, will present new product features and a compilation of new evidence that shows the benefits of its glucose biosensing technology for people with all types of diabetes at the upcoming 61st annual European Association for the Study of Diabetes (EASD) Conference.
This press release...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
15.09.2025
ISIN: US29415J1060
enVVeno Medical Corporation
NVNO
LISTED
NASDAQ
enVVeno Medical Updates Regulatory Status of VenoValve(R)
News Preview
IRVINE, CA / ACCESS Newswire / September 15, 2025 / enVVeno Medical Corporation (Nasdaq:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of deep venous disease, today announced that it will file a request for supervisory appeal of the not-approvable letter from the Center for Devices...
Themefolio
Profiler
Peergroup
© BusinessWire
15.09.2025
ISIN: US71377E1055
Performant Healthcare, Inc.
PHLT
LISTED
NASDAQ
Shareholder Alert: The Ademi Firm Continues to Investigate Whether Performant Healthcare Inc. is Obtaining a Fair Price for its Public Shareholders
News Preview
The Ademi Firm continues to investigate Performant (NASDAQ: PHLT) for possible breaches of fiduciary duty and other violations of law in its transaction with Machinify.
Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995. There is no cost or obligatio...
Themefolio
Profiler
Peergroup
© BusinessWire
15.09.2025
ISIN: US8523123052
STAAR Surgical Co
STAA
LISTED
NASDAQ
Shareholder Alert: The Ademi Firm Continues to Investigate Whether STAAR Surgical Company Is Obtaining a Fair Price for Its Public Shareholders
News Preview
The Ademi Firm continues to investigate STAAR (NASDAQ: STAA) for possible breaches of fiduciary duty and other violations of law in its transaction with Alcon Inc.
Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995. There is no cost or obligation to...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
15.09.2025
ISIN: US60785L2079
Modular Medical, Inc.
MODD
LISTED
NASDAQ
Modular Medical Receives IRB Approval for Pivot Insulin Delivery System Feasibility Study
News Preview
-Study to Evaluate Usability and Extended Wear for Next-Generation Tubeless Patch Pump SAN DIEGO, CA / ACCESS Newswire / September 15, 2025 / Modular Medical, Inc. (NASDAQ:MODD) ("Modular Medical" or the "Company"), a leader in innovative insulin delivery technology targeting the $3 billion adult "almost-pumpers" diabe...
Themefolio
Profiler
Peergroup
© BusinessWire
15.09.2025
ISIN: US14179K1016
CARGO Therapeutics Inc
CRGX
LISTED
NASDAQ
Shareholder Alert: The Ademi Firm Continues to Investigate Whether CARGO Therapeutics, Inc. is Obtaining a Fair Price for its Public Shareholders
News Preview
The Ademi Firm is investigating CARGO (NASDAQ: CRGX) for possible breaches of fiduciary duty and other violations of law in its transaction with Concentra Biosciences.
Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995. There is no cost or obligation...
Themefolio
Profiler
Peergroup
© BusinessWire
15.09.2025
ISIN: US09627Y1091
Blueprint Medicines Corp
BPMC
LISTED
NASDAQ
Shareholder Alert: The Ademi Firm Continues to Investigate the Blueprint Medicines Corporation Transaction
News Preview
The Ademi Firm is investigating Blueprint (Nasdaq: BPMC) and its transaction with Sanofi.
Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995. There is no cost or obligation to you.
In the transaction, Blueprint insiders received substantial benefit...
Themefolio
Profiler
Peergroup
© EQS Newswire
15.09.2025
ISIN: CH1330780979
Curatis Holding AG
CURN
LISTED
SIX
Double-digit growth in core business and
development milestone achieved for C-PTBE-01
News Preview
Ad hoc announcement pursuant to Art. 53 LR
Liestal, Switzerland, 15 September 2025: Curatis Holding AG (SIX:CURN) reports revenues of CHF 5.2m for H1 2025, a like for like yoy growth of 14% vs 6 months of revenues of Curatis AG in 2024. In addition, Curatis was able to sign a significant partnership with Phoenix Labs, Ireland, adding 4 products tha......
Themefolio
Profiler
Peergroup
© EQS Newswire
15.09.2025
ISIN: CH0012549785
Sonova Holding AG
SOON
LISTED
SIX
Eric Bernard takes over as Sonova CEO effective September 15, 2025
News Preview
Sonova Holding AG
/ Key word(s): Personnel
Eric Bernard takes over as Sonova CEO effective September 15, 2025
15.09.2025 / 07:00 CET/CEST
Group Media & Investor Release
Staefa (Switzerland), September 15, 2025 – Sonova Holding AG (SWX: SOON), a leading provider of innovative hearing care solutions, announces that Er......
Themefolio
Profiler
Peergroup
© EQS Newswire
15.09.2025
ISIN: CH0012549785
Sonova Holding AG
SOON
LISTED
SIX
Eric Bernard übernimmt als Sonova CEO per 15. September 2025
News Preview
Sonova Holding AG
/ Schlagwort(e): Personalie
Eric Bernard übernimmt als Sonova CEO per 15. September 2025
15.09.2025 / 07:00 CET/CEST
Group Media & Investor Release
Stäfa (Schweiz), 15. September 2025 – Sonova Holding AG (SWX: SOON), ein führender Anbieter innovativer Hörlösungen, gibt bekannt, dass Eric Bernard he......
Themefolio
Profiler
Peergroup
© BusinessWire
15.09.2025
ISIN: FR0010331421
Innate Pharma SA
IPH
LISTED
EURONEXT
Innate Pharma Announces Its Participation in the 25th Edition of the European Midcap Event
News Preview
Regulatory News:
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that Frédéric Lombard, Chief financial Officer of the Company, will participate in the 25th edition of the European Midcap Event being held from September 30 to October 1, 2025 in Paris, France.
The European Midcap Event is a key g...
Themefolio
Profiler
Peergroup
© BusinessWire
15.09.2025
ISIN: CH1330780979
Curatis Holding AG
CURN
LISTED
SIX
Curatis: Double-Digit Growth in Core Business and Development Milestone Achieved for C-PTBE-01
News Preview
Curatis Holding AG (SIX:CURN) reports revenues of CHF 5.2m for H1 2025, a like for like yoy growth of 14% vs 6 months of revenues of Curatis AG in 2024. In addition, Curatis was able to sign a significant partnership with Phoenix Labs, Ireland, adding 4 products that generated approximately CHF 5m of revenues in 2024. The loss for the period amoun...
Themefolio
Profiler
Peergroup
© PR Newswire
15.09.2025
ISIN: KYG0146B1032
Akeso, Inc.
9926
LISTED
HKSE
Akeso Announces First Patient Dose in Global Registrational Trial of Cadonilimab (PD-1/CTLA-4) for PD-1 Treatment-Resistant Hepatocellular Carcinoma
News Preview
HONG KONG, Sept. 15, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that the first patient has been dosed in its global, multicenter, randomized Phase II registrational trial (COMPASSION-36/AK104-225). The trial will evaluate cadonilimab, Akeso's first-in-class PD-1/CTLA-4 bispecific antibody, in combination with...
Themefolio
Profiler
Peergroup
© PR Newswire
15.09.2025
ISIN: AU000000ADR1
Adherium Limited
ADR
LISTED
ASX
New Data, iCARE Study: Hailie® Smartinhaler® Powers Unprecedented Medication Adherence in Patients with COPD and Asthma
News Preview
Highlights:
Up to 235% increase in real-world adherence compared to published norms (20–40%), across ~850 chronic obstructive pulmonary disease (COPD) and asthma patients.>60% patients achieved an average two-week baseline adherence with ~4 in 10 patients reaching the critical threshold of >80% adherence, a level associated with 50% fewer e...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
15.09.2025
ISIN: CA98421R1055
XPhyto Therapeutics Corp.
XPHY
LISTED
CSE
BioNxt Advances Semaglutide Oral Dissolvable Film (ODF) Program with Successful Proof-of-Concept and Prototype Development
News Preview
VANCOUVER, BC / ACCESS Newswire / September 15, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:XPHYF)(FSE:4XT) is pleased to announce the successful completion of proof-of-concept trials for its Semaglutide oral dissolvable film ("ODF") program at Vektor Pharma TF GmbH ("Vektor Pharma&qu...
Themefolio
Profiler
Peergroup
© PR Newswire
15.09.2025
ISIN: KR7145020004
Hugel, Inc.
145020
LISTED
KOE
Hugel hosts global H.E.L.F. symposium, marking 15 years of botulinum toxin Letybo
News Preview
- It highlights K-beauty values and global medical aesthetic trends- The event welcomes around 220 professionals from more than 25 countries - The program features sessions on toxin, hyaluronic acid filler, and suture
SEOUL, South Korea, Sept. 14, 2025 /PRNewswire/ -- Hugel Inc., a leading global medical aesthetics company, hosted its global medi...
Themefolio
Profiler
Peergroup
© PR Newswire
15.09.2025
ISIN: JP3435750009
M3 Inc
MTHRF
LISTED
OTC
EverBridge Group and Cosmotec Forge Landmark Partnership
News Preview
SHANGHAI, Sept. 15, 2025 /PRNewswire/ -- EverBridge Group announced an Exclusive Commercialization Partnership with Cosmotec Inc. (a Wholly Owned Subsidiary of M3, Inc.; TSE: 2413) for the Japanese market.
This strategic collaboration underscores EverBridge Group's leadership in proprietary R&D, stringent regulatory compliance, and value-dri...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
15.09.2025
ISIN: GB00BP2C3V08
Genflow Biosciences Plc
GENF
LISTED
LSE
Genflow Signs CDAs with Animal Health Companies
News Preview
Genflow Signs CDAs with Animal Health Companies to Advance Longevity Gene Therapy Platform LONDON, UK / ACCESS Newswire / September 15, 2025 / Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) ("Genflow" or "the Company"), the only publicly listed longevity company in Europe, today announces that it has signed two Confidential Dis...
Themefolio
Profiler
Peergroup
© PR Newswire
15.09.2025
ISIN: KYG3224E1061
Everest Medicines Limited
1952
LISTED
HKSE
Real-World Evidence of NEFECON® to Be Presented in Seven New Abstracts at the 18th International lgAN Symposium
News Preview
7 new NEFECON® real-world evidence abstracts will be presented at the 18th International lgA Nephropathy Symposium (IIgANN 2025).The newly released results, based on clinical practices at several leading hospitals in China, offer a comprehensive overview of the efficacy and safety of NEFECON® in the treatment of IgA nephropathy (IgAN). NEFECON® c...
Themefolio
Profiler
Peergroup
© Globe Newswire
14.09.2025
ISIN: AU000000AVH4
Avita Medical Inc.
AVH
LISTED
ASX
AVITA Medical Receives CE Mark for RECELL® GO, Enabling Commercialization Across Europe
News Preview
AVITA Medical has received the CE Mark for RECELL GO. This mark enables AVITA to begin commercializing RECELL GO across Europe....
Themefolio
Profiler
Peergroup
© PR Newswire
14.09.2025
ISIN: US81684M1045
Semler Scientific Inc
SMLR
LISTED
NASDAQ
SMLR Investors Have Opportunity to Lead Semler Scientific, Inc. Securities Fraud Lawsuit First Filed by The Rosen Law Firm
News Preview
NEW YORK, Sept. 14, 2025 /PRNewswire/ --
Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Semler Scientific, Inc. (NASDAQ: SMLR) between March 10, 2021 and April 15, 2025, both dates incl...
Themefolio
Profiler
Peergroup
© PR Newswire
14.09.2025
ISIN: US5165441032
Lantheus Holdings Inc
LNTH
LISTED
NASDAQ
LNTH INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Lantheus Holdings, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
News Preview
NEW YORK, Sept. 14, 2025 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Lantheus Holdings, Inc. ("Lantheus" or "the Company") (NASDAQ: LNTH) and certain of its officers....
Themefolio
Profiler
Peergroup
© PR Newswire
14.09.2025
ISIN: US5165441032
Lantheus Holdings Inc
LNTH
LISTED
NASDAQ
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Lantheus
News Preview
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Lantheus To Contact Him Directly To Discuss Their Options
If you suffered losses exceeding $75,000 in Lantheus between February 26, 2025 and August 5, 2025 and would like to discuss your legal rights, call Faruq...
Themefolio
Profiler
Peergroup
© Globe Newswire
14.09.2025
ISIN: US61023L1089
Monopar Therapeutics Inc
MNPR
LISTED
NASDAQ
Monopar to Present New Long-Term Neurological Efficacy and Safety Data for ALXN1840 in Wilson Disease at the 150th American Neurological Association Annual Meeting
News Preview
WILMETTE, Ill., Sept. 14, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today announced that new data on the long-term neurological efficacy and safety of its investigational therapy...
Themefolio
Profiler
Peergroup
© BusinessWire
14.09.2025
ISIN: US02157Q1094
Alto Neuroscience, Inc.
ANRO
LISTED
NYSE
ANRO Deadline: Rosen Law Firm Urges Alto Neuroscience, Inc. (NYSE: ANRO) Stockholders to Contact the Firm for Information About Their Rights
News Preview
Rosen Law Firm, a global investor rights law firm, reminds investors that a shareholder filed a class action on behalf of purchasers of common stock of Alto Neuroscience, Inc. (NYSE: ANRO): (i) pursuant and/or traceable to Alto’s initial public offering conducted on or about February 2, 2024 (the “IPO”); and/or (ii) securities between February 2,...
Themefolio
Profiler
Peergroup
© BusinessWire
13.09.2025
ISIN: US6404911066
Neogen Corp
NEOG
LISTED
NASDAQ
NEOG Deadline: Rosen Law Firm Urges Neogen Corporation (NASDAQ: NEOG) Stockholders to Contact the Firm for Information About Their Rights
News Preview
Rosen Law Firm, a global investor rights law firm, reminds investors that a shareholder filed a class action on behalf of purchasers of common stock of Neogen Corporation (NASDAQ: NEOG) between January 5, 2023 and June 3, 2025. Neogen describes itself as a “food safety company that manufactures and markets products and services dedicated to food a...
Themefolio
Profiler
Peergroup
© PR Newswire
13.09.2025
ISIN: US8342033094
Soleno Therapeutics Inc
SLNO
LISTED
NASDAQ
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Soleno Therapeutics, Inc.- SLNO
News Preview
NEW YORK, Sept. 13, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Soleno Therapeutics, Inc. ("Soleno" or the "Company") (NASDAQ: SLNO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980....
Themefolio
Profiler
Peergroup
© PR Newswire
13.09.2025
ISIN: US05463X1063
AxoGen Inc
AXGN
LISTED
NASDAQ
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Axogen, Inc. - AXGN
News Preview
NEW YORK, Sept. 13, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Axogen, Inc. ("Axogen" or the "Company") (NASDAQ: AXGN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980....
Themefolio
Profiler
Peergroup
© PR Newswire
13.09.2025
ISIN: US00847X1046
Agios Pharmaceuticals Inc
AGIO
LISTED
NASDAQ
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Agios Pharmaceuticals, Inc. - AGIO
News Preview
NEW YORK, Sept. 13, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Agios Pharmaceuticals, Inc. ("Agios" or the "Company") (NASDAQ: AGIO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980....
Themefolio
Profiler
Peergroup
© PR Newswire
13.09.2025
ISIN: US90466Y1038
Unicycive Therapeutics, Inc.
UNCY
LISTED
NASDAQ
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Unicycive Therapeutics
News Preview
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Unicycive To Contact Him Directly To Discuss Their Options
If you suffered losses exceeding $50,000 in Unicycive between March 29, 2024 and June 27, 2025 and would like to discuss your legal rights, call Faruqi...
Themefolio
Profiler
Peergroup
© PR Newswire
13.09.2025
ISIN: US67079U3068
Nutex Health Inc
NUTX
LISTED
NASDAQ
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Nutex Health
News Preview
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Nutex To Contact Him Directly To Discuss Their Options
If you suffered losses exceeding $50,000 in Nutex between August 8, 2024 and August 15, 2025 and would like to discuss your legal rights, call Faruqi &...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
